Does Reducing LDL to Ultra-low Level (<25 mg/dL) have Additional Benefit on CVD Events or Safety Concerns?


Dr AK Pancholia, Indore    19 December 2017

increase in clinical and lab side effects vs. those with higher LDL-C or control groups in properly randomized studies.

The CVD events and IVUS data show additional benefits from low  (<40 mg/dL) and very low (<25 mg/dL) levels of LDL and increase CVD events when LDL remained elevated.

These evidences are derived from recent PCSK9 inhibitor trials, ODYSSEY LONG TERM (Alirocumab) and FOURIER (Evolocumab). Based on current evidence, the real safety concern is undertreatment of LDL rather than very low LDL. It is very hard to argue that we should reduce the dose of statin simply because the LDL is very low.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.